novan
provides
pipeline
priority
development
programs
update
lead
product
candidate
currently
evaluated
pivotal
phase
study
molluscum
contagiosum
topline
data
targeted
vitro
assessments
ability
inhibit
replication
mechanisms
underway
key
findings
targeted
year
end
exploratory
work
evaluate
antimicrobial
indications
companion
animal
health
initiated
ongoing
review
existing
programs
opportunities
expand
priority
development
pipeline
morrisville
globe
newswire
novan
company
novan
nasdaq
novn
today
provided
priority
pipeline
update
addition
focusing
primary
efforts
toward
lead
product
candidate
molluscum
company
also
directing
development
activities
toward
ongoing
vitro
work
related
coronaviridae
well
exploring
potential
platform
technology
use
antimicrobial
indication
companion
animal
health
course
past
months
dedicated
time
efforts
evaluating
internal
pipeline
assets
broader
dermatology
platform
underlying
technology
components
represent
believe
solid
foundation
build
momentum
support
novan
next
phase
growth
commented
paula
brown
stafford
chairman
president
chief
executive
officer
novan
focused
successfully
executing
pivotal
phase
study
treatment
molluscum
underway
dosing
patients
pleased
progress
team
continued
make
important
stafford
continued
additionally
continued
make
progress
vitro
work
evaluate
ability
target
replication
mechanisms
target
reporting
key
findings
assessments
year
end
also
pleased
announce
launched
exploratory
efforts
evaluate
use
antimicrobial
indications
companion
animal
health
area
believe
diversifies
pipeline
provides
opportunities
adjacent
yet
important
topical
antiviral
gel
treatment
viral
skin
infections
current
focus
treatment
molluscum
contagiosum
contagious
skin
infection
caused
molluscipoxvirus
dna
virus
program
highlights
pivotal
phase
study
treatment
molluscum
underway
target
completion
enrollment
topline
results
targeted
subject
timing
trial
execution
plan
may
impacted
pandemic
information
trial
please
visit
reference
identifier
coronaviridae
currently
conducting
vitro
assessments
evaluate
ability
inhibit
replication
mechanisms
program
highlights
nitric
oxide
may
inhibit
viral
replication
cytotoxic
reactions
intermediates
peroxynitrite
vitro
assessments
targeting
reduction
viral
shedding
transmission
targeting
year
end
report
findings
vitro
assessments
companion
animal
program
initiated
exploratory
work
evaluate
potential
product
candidate
antimicrobial
indications
companion
animal
health
program
highlights
contracted
drug
delivery
technology
specialist
undertake
initial
formulation
development
assess
viability
engaged
animal
health
experts
assess
technical
feasibility
market
potential
target
seeking
potential
strategic
partner
collaborator
following
initial
work
addition
advancing
priority
development
programs
also
rich
pipeline
potential
expansion
opportunities
dermatology
men
women
health
gastroenterology
conditions
significant
unmet
needs
continuing
review
existing
programs
opportunities
could
expand
priority
development
efforts
concluded
stafford
novan
novan
clinical
biotechnology
company
focused
leveraging
proprietary
nitric
oxide
based
technology
platform
generate
macromolecular
new
chemical
entities
nce
treat
multiple
indications
dermatology
men
women
health
infectious
diseases
gastroenterology
conditions
significant
unmet
needs
company
lead
product
candidate
topical
antiviral
gel
treatment
molluscum
contagiosum
currently
evaluated
pivotal
phase
clinical
study
company
believes
topical
therapy
rapid
treatment
benefit
approved
would
address
important
need
treatment
molluscum
statements
press
release
contains
statements
including
limited
statements
related
pharmaceutical
development
nitric
product
candidates
intention
advance
development
certain
product
candidates
timing
reporting
findings
results
programs
currently
process
statements
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
expectations
including
limited
risks
uncertainties
ongoing
future
product
development
activities
preclinical
studies
may
prove
successful
demonstrating
concept
may
show
adverse
toxicological
findings
even
successful
may
necessarily
predict
subsequent
clinical
trials
show
requisite
safety
efficacy
product
candidates
risks
uncertainties
clinical
development
process
including
among
others
length
expense
ability
enroll
patients
reliance
third
parties
potential
delays
impacts
whether
result
pandemic
factors
results
earlier
research
preclinical
clinical
trials
may
predictive
results
conclusions
interpretations
later
research
activities
additional
trials
risks
related
regulatory
approval
process
lengthy
inherently
unpredictable
including
risk
product
candidates
may
approved
additional
studies
may
required
approval
delays
may
occur
may
obtain
funding
sufficient
complete
regulatory
development
process
ability
obtain
additional
funding
enter
strategic
business
relationships
necessary
useful
development
product
candidates
risk
disruptions
fda
agencies
could
cause
agencies
cancel
postpone
meetings
otherwise
impact
ability
agencies
provide
regulatory
guidance
feedback
timely
review
process
regulatory
submissions
could
material
adverse
effect
business
risks
related
manufacture
clinical
trial
materials
operational
disruptions
result
pandemic
including
delays
disruptions
enrollment
conduct
phase
trial
risks
uncertainties
described
annual
report
filed
sec
form
twelve
months
ended
december
amended
subsequent
filings
sec
statements
speak
date
press
release
novan
disclaims
intent
obligation
update
statements
reflect
events
circumstances
date
statements
except
may
required
law
investor
media
contact
jenene
thomas
jtc
team
llc
novn
